Norfloxacin in the treatment of uncomplicated gonococcal infections.
Norfloxacin, an oral fluoroquinolone antibacterial, is active in vitro against a variety of gram-positive and gram-negative pathogens, including both penicillinase-producing and non-penicillinase-producing strains of Neisseria gonorrhoeae. An earlier study demonstrated that a two-dose regimen of norfloxacin was as effective as standard therapy with spectinomycin for treating gonococcal urethritis, including infections caused by penicillinase-producing organisms. In this randomized study of treatment for uncomplicated gonococcal infection in men and women, three oral treatment regimens were compared: patients received either two doses of norfloxacin (600 mg twice daily), a single dose of norfloxacin (800 mg), or a single-dose ampicillin (3.5 g)/probenecid (1.0 g) regimen (as recommended by the Centers for Disease Control). All three treatment regimens achieved similar cure rates. Although the number of patients treated was too small to yield statistically significant conclusions, it appears that norfloxacin may be slightly better treatment for rectal and pharyngeal gonococcal infections than ampicillin and probenecid. Additionally, norfloxacin was well tolerated in this study. Thus, based on a review of these data, norfloxacin appears to be an alternative, single-dose, oral treatment regimen for uncomplicated gonococcal infection.
Kaplowitz
L G
LG
Vishniavsky
N
N
Evans
T
T
Vartivarian
S
S
Dalton
H
H
Simpson
M
M
Gruninger
R P
RP
D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009643:Norfloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011339:Probenecid / Q000627:therapeutic use; D011897:Random Allocation
D000667:Ampicillin; D009643:Norfloxacin; D011339:Probenecid